{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:46:59Z","timestamp":1775890019269,"version":"3.50.1"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The aim of this analysis was to identify therapeutic micafungin regimens for children that produce the same micafungin exposures known to be effective for the prevention and treatment of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>\n            infections in adults. Pediatric pharmacokinetic data from 229 patients between the ages of 4 months and &lt;17 years were obtained from four phase I and two phase III clinical trials. Population pharmacokinetic models were used to simulate the proportion of children who had a steady-state area under the concentration-time curve at 24 hours (AUC\n            <jats:sub>24<\/jats:sub>\n            ) of micafungin within the 10th to 90th percentile range observed in a population of adults receiving a dose of micafungin with established efficacy for invasive candidiasis (100 mg\/day), i.e., 75 to 139 \u03bcg \u00b7 h\/ml. Simulated pediatric dosages of 0.5 to 5 mg\/kg of body weight\/day were explored. A two-compartment model was used that incorporated body weight as a predefined covariate for allometric scaling of the pharmacokinetic parameters. During construction of the model, aspartate aminotransferase and total bilirubin were also identified as covariates that had a significant effect on micafungin clearance. A dose of 2 mg\/kg resulted in the highest proportion of children within the predefined micafungin AUC\n            <jats:sub>24<\/jats:sub>\n            target range for invasive candidiasis. Cutoffs of 40 or 50 kg for weight-based dosing resulted in heavier children being appropriately dosed. Thus, dose regimens of 1, 2, and 3 mg\/kg\/day micafungin are appropriate for the prevention of invasive candidiasis, the treatment of invasive candidiasis, and the treatment of esophageal candidiasis, respectively, in children aged 4 months to &lt;17 years.\n          <\/jats:p>","DOI":"10.1128\/aac.03736-14","type":"journal-article","created":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T04:28:59Z","timestamp":1416889739000},"page":"905-913","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents"],"prefix":"10.1128","volume":"59","author":[{"given":"William W.","family":"Hope","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Kaibara","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roy","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Children's Hospital of Orange County, Division of Infectious Disease, Orange, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nkechi","family":"Azie","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Kovanda","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Mycamine: summary of product characteristics","author":"Astellas Pharma GmbH","year":"2008","unstructured":"Astellas Pharma GmbH. 2008. Mycamine: summary of product characteristics. Astellas Pharma GmbH, Munich, Germany."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_3_2_4_2","volume-title":"Mycamine (micafungin sodium) package insert","author":"Astellas Pharma GmbH","year":"2013","unstructured":"Astellas Pharma GmbH. 2013. Mycamine (micafungin sodium) package insert. Astellas Pharma GmbH, Munich, Germany."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000245103.07614.e1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3317-3324.2005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00398-07"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01679-09"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/422312"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60605-9"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.03.003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12025"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31829efd14"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31817275e6"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2007.09.018"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.200"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181910e2d"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.10.1266"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/524063"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02114.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03736-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03736-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:53:28Z","timestamp":1645484008000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03736-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1128\/AAC.03736-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03736-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"2014-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}